Table 3. Time receiving maintenance... | American Society of Hematology

Table 3.

Time receiving maintenance therapy, and reasons for early termination

	All patients (n = 97)	alloHCT (n = 75)	HiDAC (n = 22)	P
Months, median (range)	9 (1-13)	9 (1-13)	10.5 (1-12)	.82
Early termination, n (%)
Total	60 (61.8)	44 (58.7)	16 (72.7)	.32
Death	1 (1.7)	1 (2.3)	0	.99
IC/patients’ wish	11 (18.3)	11 (25)	0	.06
Midostaurin toxicity	28 (46.6)	24 (54.55)	4 (25)	.29
Other reasons*	7 (11.7)	2 (4.55)*	5 (31.25)†	.006
Relapse	13 (21.7)	6 (13.6)	7 (43.75)	.009

	All patients (n = 97)	alloHCT (n = 75)	HiDAC (n = 22)	P
Months, median (range)	9 (1-13)	9 (1-13)	10.5 (1-12)	.82
Early termination, n (%)
Total	60 (61.8)	44 (58.7)	16 (72.7)	.32
Death	1 (1.7)	1 (2.3)	0	.99
IC/patients’ wish	11 (18.3)	11 (25)	0	.06
Midostaurin toxicity	28 (46.6)	24 (54.55)	4 (25)	.29
Other reasons*	7 (11.7)	2 (4.55)*	5 (31.25)†	.006
Relapse	13 (21.7)	6 (13.6)	7 (43.75)	.009

IC, withdrawal of informed consent.

Thrombocytopenia, lung cancer.

Molecular relapse, myelodysplastic syndrome, accidental mistake in midostaurin intake (n = 2), lost to follow-up.